First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension

Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3

Irvine, California, UNITED STATES

LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body. NAD+ declines as we age and is a critical coenzyme for cellular energy production and mitochondrial function, both important components of healthy human aging.

About one third of U.S. adults have hypertension, putting them at greater risk of cardiovascular disease, or even death. The benefits of exercise in helping to manage hypertension and enhance cardiovascular health are well documented. However, as individuals age, continuing a regular exercise routine can become more challenging due to age-associated physiological declines.

“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,” said primary investigator Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida.

This new randomized, double-blind study will evaluate the impact of NR supplementation combined with exercise in 74 hypertensive adults as measured by changes in arterial stiffness, blood pressure and walking performance. It was initiated as part of the ChromaDex External Research Program (CERP), where ChromaDex supplies its NR and placebo at no cost to research institutions worldwide.

“Through increases in NAD+, NR has the potential to improve cellular energy production, supplying individuals with the energy necessary to maintain a regular exercise routine,” said ChromaDex Chief Scientific Officer Dr. Matthew Roberts. “We look forward to enhancing our understanding of the use of NR as an adjuvant approach to exercise in promoting improvements in the cardiovascular health of aging adults.”

Niagen is the only commercially available nicotinamide riboside which has twice been successfully reviewed under FDA's new dietary ingredient (NDI) notification program and has also been successfully notified to the FDA as generally recognized as safe (GRAS).

For additional information on the science supporting Niagen visit

About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to NR’s ability to enhance the effects of exercise therapy in older adults with hypertension. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Media Contact:
Alex Worsham, Senior Director of Global Corporate Communications
310-388-6706 ext. 689

ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations
949-419-0288 ext. 127